Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab Announces U.S. FDA Approval of DARZALEX(TM) (daratumumab) for Multiple Myeloma and Updates Financial Guidance

GlobeNewswire November 16, 2015

Genmab Announces Financial Results for the First Nine Months of 2015 and Improves 2015 Financial Guidance

GlobeNewswire November 3, 2015

Genmab Achieves $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen

GlobeNewswire October 25, 2015

Major shareholder announcement for Genmab A/S

GlobeNewswire October 23, 2015

Major Shareholder Announcement

GlobeNewswire October 16, 2015

Major Shareholder Announcement

GlobeNewswire October 8, 2015

Genmab Reaches $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen

GlobeNewswire October 5, 2015

Major Shareholder Announcement

GlobeNewswire September 29, 2015

CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma

GlobeNewswire September 25, 2015

U.S. FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire September 19, 2015

Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma

GlobeNewswire September 9, 2015

U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma

GlobeNewswire September 4, 2015

Major Shareholder Announcement

GlobeNewswire September 2, 2015

Data Published in The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses in Heavily Pre-treated Relapsed or Refractory Multiple Myeloma Patients

GlobeNewswire August 27, 2015

Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology

GlobeNewswire August 14, 2015

Genmab Announces Financial Results for the First Half of 2015

GlobeNewswire August 12, 2015

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire July 22, 2015

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire July 22, 2015

Major Shareholder Announcement for Genmab A/S

GlobeNewswire July 10, 2015

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone

GlobeNewswire July 9, 2015